Cellectis Gains FDA Designations for Leukemia Therapy
Company Announcements

Cellectis Gains FDA Designations for Leukemia Therapy

Cellectis SA (CLLS) has released an update.

Cellectis SA’s UCART22, a gene-edited CAR T-cell product candidate, has received Orphan Drug and Rare Pediatric Disease Designations from the FDA for its potential to treat Acute Lymphoblastic Leukemia (ALL), a rapidly progressing and typically fatal disease if untreated. This recognition could accelerate and reduce costs of development and approval, and suggests UCART22 as a promising therapy for ALL patients who have limited treatment options. Encouraging clinical data indicates a high preliminary response rate, with further updates expected by year-end 2024.

For further insights into CLLS stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskCellectis S.A. Reports Q3 2024 Financial Results and Updates
TipRanks Auto-Generated NewsdeskCellectis SA Advances CAR T-cell Therapy for Solid Tumors
TheFlyCellectis price target lowered to $5 from $7 at Barclays
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App